MetaCap

Prelude Therapeutics Incorporated (PRLD)

NASDAQ: PRLDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.23-0.025 (-0.77%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PRLD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$258.63M
EPS (TTM)
-$0.59
52-week range
1.30 – 6.83
Day range
3.17 – 3.30
Volume / Avg
299.25K / 432.74K
Beta
—

52-week range

$1.30$6.83

PRLD stock today

On Nov 20, PRLD ended the session at $3.23, shedding $0.025 (0.77%), versus the S&P 500's 3.70% decline. At this level, PRLD sits in the middle of its 52-week range of $1.30 to $6.83: 52.7% below the high, set on Aug 24, 2026 and 149.4% above the low. PRLD is up 11.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 93.4%.

Prelude Therapeutics has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Prelude Therapeutics

Company profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Krishna Vaddi D.V.M., Ph.D.
Headquarters
Wilmington, DE
Employees
79
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Prelude Therapeutics generated $12.1 million in revenue, up 73.4% from fiscal 2024. Prelude Therapeutics reported a net loss of $99.5 million, compared with a loss of $127.2 million a year earlier. Operating margin was -861.3%.

Prelude Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$12.14M$7.00M———
Growth+73.43%————
Net income$-99.50M$-127.17M$-121.83M$-115.44M$-111.69M
EPS (diluted)$-1.29$-1.68$-2.02$-2.44$-2.43

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$8.80+172.45%

  • Strong buy 2
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.12 vs $-0.14
Surprise
+14.29%

PRLD news

All PRLD news

Prelude Therapeutics peers

Health Care sector
PRLD peer companies
CompanyPrice% ChgMarket capCompare
EBSEmergent BioSolutions Inc.5.05-1.94%$259.65Mvs PRLD
ALTAltimmune Inc.1.33-5.67%$258.80Mvs PRLD
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs PRLD
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs PRLD
QTTBQ32 Bio Inc.8.34-1.65%$249.57Mvs PRLD
TTRXTurn Therapeutics Inc.8.10-6.31%$247.49Mvs PRLD
LFCRLifecore Biomedical Inc.6.39+0.31%$242.22Mvs PRLD
RLMDRelmada Therapeutics Inc.2.62-15.76%$279.54Mvs PRLD

Indexes, lists and sector

Prelude Therapeutics stock FAQ

What is Prelude Therapeutics's stock price today?

PRLD last traded at $3.23 as of Nov 20, 4:00 PM EST, down 0.77% on the day. Prices are delayed at least 15 minutes.

Who is Prelude Therapeutics's CEO?

Dr. Krishna Vaddi D.V.M., Ph.D. is the chief executive officer of Prelude Therapeutics Incorporated, which has about 79 employees.

What is the PRLD 52-week high?

The 52-week high for PRLD is $6.83 and the 52-week low is $1.30. The stock is currently 52.7% below its high.

Compare PRLD